# Project MT4 — Mitigate (ACD&P)

**Program element:** 0603884BP — Chemical and Biological Defense Program - Dem/Val  
**Project:** MT4  
**Component:** Defense-Wide  
**Appropriation:** 0400 — RDT&E, Defense-Wide  
**Budget Activity:** 4 — Advanced Component Development & Prototypes  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0603884BP/MT4  
**Parent:** https://hitchintel.com/programs/0603884BP

## Summary

Project MT4 — Mitigate (ACD&P) requests $55.3M in FY2027, 14% of the $391.3M requested for program element 0603884BP, up 106% on FY2026. 7 R-2A activities decompose the request, 2 new this cycle. JPM CBRN Medical, CPE CBRND is the largest named R-3 performer at $1.0M, 1.8% of the project's FY2027 R-3 total.

## Funding profile

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 33.6 |
| FY2026 | Enacted | 26.8 |
| FY2027 | Request | 55.3 |
| FY2028 | Outyear | 54.3 |
| FY2029 | Outyear | 46.7 |
| FY2030 | Outyear | 52.2 |
| FY2031 | Outyear | 53.1 |

> Estimate types are not summed. This project is one leaf of PE 0603884BP; the PE total is the sum of its projects, never added to them.

## What project MT4 buys

The Mitigate Advanced Component Development and Prototypes (ACD&P) Project provides the Joint Force the ability to conduct decontamination and medical actions that enable the quick restoration of combat power; maintain/recover essential functions that are free from the effects of chemical and biological (CB) hazards; and facilitate the return to pre-incident operational capability as soon as possible. Efforts included in this Project are: (1) Autonomous Decontamination System (ADS) - Prototype Development (2) Agent-Directed Therapeutics (AD TX) - Clinical (3) Broadening Enabling Acquisition of Chemical Operational Needs (BEACON) (4) Host-Directed Therapeutics (HD TX) - Evaluation of Host Directed Candidates/Non Clinical Studies (5) Reactivating Nerve Agent Treatment System (RNATS) (6) Anti-Viral Oral Therapeutics (AVO TX) - Development Test and Evaluation (7) Botulinum Toxin Therapeutic (BOT TX) - Non-clinical Studies

**R-3 lines of work:** Product Development; Support; Test and Evaluation; Management Services.

## Named R-3 performers

| Performer | $M | Share of this project's FY2027 R-3 total |
|---|---|---|
| JPM CBRN Medical, CPE CBRND | 1.0 | 1.8% |

> Budget-justification contract funding, not obligations. Shares need not reach 100% — unnamed and government work is in the denominator.

## Activities (R-2A) — 7

| Activity | FY2025 | FY2026 | FY2027 | Move | Page |
|---|---|---|---|---|---|
| 2) Agent-Directed Therapeutics (AD TX) - Clinical | 5.3 | 13.2 | 19.7 | +50% | — |
| 3) Broadening Enabling Acquisition of Chemical Operational Needs (BEACON) | — | — | 18.3 | new | — |
| 1) Autonomous Decontamination System (ADS) - Prototype Development | 3.0 | 7.5 | 10.0 | +33% | [a0](https://hitchintel.com/programs/0603884BP/MT4/a0) |
| 4) Host-Directed Therapeutics (HD TX) - Evaluation of Host Directed Candidates/MDD/Non Clinical Studies | — | — | 7.3 | new | — |
| 5) Reactivating Nerve Agent Treatment System (RNATS) | 9.0 | 6.2 | — | −100% | — |
| 6) Anti-Viral Oral Therapeutics (AVO TX) - Model Development Studies | 11.9 | — | — | — | — |
| 7) Botulinum Toxin Therapeutic (BOT TX) - Non-clinical Studies | 4.4 | — | — | — | — |

> Activities carry the prior, current and budget year only — no five-year plan. In the request year they partition this project exactly; in earlier years they can under-cover it.

### 2) Agent-Directed Therapeutics (AD TX) - Clinical

**FY2027 planned work.** Phase 2 clinical trial completion and execution of drug product manufacturing to support Phase 3 studies.

**FY2026 to FY2027 change.** Increase is due to execution of Phase 2 clinical trial and drug product manufacturing for Phase 3 clinical trial.

**FY2026 plans — current year.** Drug product scale-up for execution of the Phase 2 Clinical Trial. Initiation of Phase 2 trial.

**FY2025 accomplishments.** Produced Active Pharmaceutical Ingredients (API) for drug product scale up to support execution of the Phase 2 clinical trial. Initiated Phase 2 preparation activities.

### 3) Broadening Enabling Acquisition of Chemical Operational Needs (BEACON) — NEW START

**FY2027 planned work.** Initiate non-clinical testing of multiple candidates.

**FY2026 to FY2027 change.** Increased investment provides enabling capability to accelerate medical countermeasure candidate identification and screening to streamline evaluation and expedite non-clinical testing.

### 1) Autonomous Decontamination System (ADS) - Prototype Development

Receive Phase II prototypes and conduct a Soldier Touch Point (STP) and limited government testing. Down select and award a Phase III contract to 1-2 vendor(s) to refine their prototypes further based on test results and feedback. Complete Phase III Contractor Qualification Testing (QT) and receive prototype(s) in preparation for another…

Full year-by-year narrative: https://hitchintel.com/programs/0603884BP/MT4/a0

### 4) Host-Directed Therapeutics (HD TX) - Evaluation of Host Directed Candidates/MDD/Non Clinical Studies — NEW START

**FY2027 planned work.** Initiate the evaluation of Host Directed candidates and execute initial non clinical studies.

**FY2026 to FY2027 change.** Increased investment enables improved Host Directed medical countermeasure development through a next generation initiative providing a pipeline of efforts enabling therapeutic solutions.

### 5) Reactivating Nerve Agent Treatment System (RNATS)

**FY2026 to FY2027 change.** Funding decrease due to program closeout and transition to Rapid Access Products in Development (RAPID).

**FY2026 plans — current year.** Conduct nonclinical studies, collaborate with internal government partners, increase engagement with stakeholders and industry.

**FY2025 accomplishments.** Initiated drug development, initiated manufacturing and systems engineering.

### 6) Anti-Viral Oral Therapeutics (AVO TX) - Model Development Studies

**FY2025 accomplishments.** Continued Natural History Studies with procurement of long lead items and received FDA feedback on the regulatory strategy.

### 7) Botulinum Toxin Therapeutic (BOT TX) - Non-clinical Studies

**FY2025 accomplishments.** Completed Animal model development and Natural History studies. Due to technical issues with the product in S&T, program is ending in FY25 following receipt of deliverables.

## What is NOT on this page

Congressional marks, the R-2 mission description and acquisition strategy, the industry vs government split of the whole request, and related program elements are recorded at **program-element** grain — an NDAA mark lands on a PE, never on a project. They are at https://hitchintel.com/programs/0603884BP.

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibits R-2/R-2A/R-3, PE 0603884BP project MT4 (PB PB2027).
- **MCP:** `mcp.hitchintel.com` — `budget_get_program_element(pe="0603884BP")`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*